Weekender 9/11/15

To Our New Jersey Life Sciences Community:
Welcome to another edition of the Weekender.

New Jersey’s life sciences ecosystem continues to develop and invest in new treatments and cures for the patients who need them…

A number of major New Jersey pharmaceutical companies are being monitored for progress on cancer cures. A report set to be released next Wednesday names more than 30 companies, including 18 BioNJ Members such as Merck, Bristol-Myers Squibb, Novartis and Sanofi U.S. The important work being done by these and other companies listed within the report will play an integral role in identifying new, more effective therapies to help people with cancer achieve positive treatment outcomes and transition from being cancer patients to cancer survivors.

In a bold move, BioNJ Member Amicus Therapeutics is acquiring Scioderm, Inc., whose lead drug candidate, Zorblisa, is a topical cream for Epidermolysis Bullosa, a chronic, genetic connective tissue disorder with no approved treatments. Both Amicus and Scioderm are wholly and passionately focused on patients with rare diseases and this combination is a major win for EB patients.

Bolstered by state resources, BioNJ Member Celator Pharmaceuticals has raised capital to fund operations and is nearing the completion of a Phase 3 clinical trial for its lead product VYXEOSTM (CPX-351), the injected therapy that treats patients with high-risk acute myeloid leukemia. When asked why they chose New Jersey for their operation, Celator replied that, “New Jersey is an excellent location for multiple reasons: the health care talent base in the area is exceptional; the focus and assistance provided by the state has significantly helped Celator, as well as other companies, advance novel products for patients; and the state is home to numerous pharmaceutical and biotechnology companies, foundations and world-renowned research organizations. These factors, along with the benefits provided by other organizations such as BioNJ, are key reasons why we chose to grow Celator in New Jersey.”

BioNJ Member Celgene Corporation announced it has closed its acquisition of Receptos, Inc. The acquisition of Receptos adds Ozanimod, a novel, potential best-in-class, oral, selective sphingosine 1-phosphate 1 and 5 receptor modulator (S1P) to Celgene’s deep and diverse pipeline of potential disease-altering medicines and investigational compounds.
Sandoz, a company of East Hanover-based BioNJ Member Novartis, announced that Zarxio(TM) (filgrastim-sndz) is the first biosimilar approved by the U.S. Food and Drug Administration and the first to launch in the U.S.

Otsuka Pharmaceutical and Proteus Digital Health announced that the FDA has determined that the New Drug Application  for the combination product of ABILIFY® (aripiprazole) embedded with a Proteus® ingestible sensor in a single tablet is sufficiently complete to allow for a substantive review and is considered filed. (This is the first Digital Medicine New Drug Application to be accepted by the FDA!)

ADC Therapeutics (ADCT) announced that it has raised $80 million to be used to progress ADCT’s product portfolio, including ADCT-301 for lymphoma and leukemia now in Phase I and a collaboration to develop up to two Antibody Drug Conjugates (ADCs)  for commercialization with MedImmune, the global biologics research and development arm of AstraZeneca.

If you have not yet registered for the 3rd Annual BioNJ CEO Summit, October 9, at the Bridgewater Marriott, we invite you to do so now. New speakers and topics are being added to the program every day. Click here to review the agenda.

Click here for this week’s Weekender.